As a result of the oncogenic activity of SHP2, several SHP2 inhibitors have been developed and evaluated in clinical trials for the treatment of solid tumours including KRAS mutant non-small cell lung cancer. The gene discussed is PTPN11; the disease is non-small cell lung carcinoma.